Bayer Attributes Recent Aleve Bounce To Advisory Panel Discussions
This article was originally published in The Tan Sheet
Executive Summary
Bayer credits a rebound in Aleve sales in March to favorable FDA advisory committee discussions on the safety of naproxen
You may also be interested in...
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany